KR920700671A - 종양세포 증식 억제제 - Google Patents

종양세포 증식 억제제

Info

Publication number
KR920700671A
KR920700671A KR1019910700779A KR910700779A KR920700671A KR 920700671 A KR920700671 A KR 920700671A KR 1019910700779 A KR1019910700779 A KR 1019910700779A KR 910700779 A KR910700779 A KR 910700779A KR 920700671 A KR920700671 A KR 920700671A
Authority
KR
South Korea
Prior art keywords
cell proliferation
tumor cell
proliferation inhibitor
residue
oligopeptide
Prior art date
Application number
KR1019910700779A
Other languages
English (en)
Inventor
구니히또 이이지마
하루끼 가또
요이찌로 나가스
Original Assignee
사까이 마사까즈
고오껜 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사까이 마사까즈, 고오껜 가부시끼가이샤 filed Critical 사까이 마사까즈
Publication of KR920700671A publication Critical patent/KR920700671A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

종양세포 증식 억제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명으 종양세포증식 억제제의 투여량에 대한 생존율이 관계를 나타내는 선도이다.

Claims (4)

  1. α-히드록시산의 저 축합물 및 중합물, 피로글루탐산을 적어도 1 잔기 함유하는 올리고펩티드 및 안정화제를 포함하는 종양세포 증식 억제제.
  2. 제1항에 있어서, α-히드록시산의 저 축합 및 중합물이 주로 α-히드록시산의 2내지 10분자를 축합 및 중합한 화합물과 그 금속염을 포함하는 종양세포 증식 억제제.
  3. 제1항에 있어서, 피로글루탐산을 적어도 1 잔기 함유하는 올리고펩티드가 2내지 8잔기의 아미노산으로 이루는 올리고펩티드이고 피로글루탐산을 적어도 1잔기 함유되는 화합물 및 그 금속염을 포함하는 종양 세포 증식 억제제.
  4. 제1항에 있어서, 그 구성성분증량비가 α-히드록시산의 저 축합물 및 중합물 10, 피로글루탐산을 적어도 1잔기 함유하는 올리고펩티드 1내지 4, 안정화제(당, 당알콜) 1내지 3인 종양 세포증식 억제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700779A 1989-12-25 1990-12-21 종양세포 증식 억제제 KR920700671A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1332870A JP2997488B2 (ja) 1989-12-25 1989-12-25 腫瘍細胞増殖抑制剤
JP1-332870 1989-12-25
PCT/JP1990/001678 WO1991009612A1 (fr) 1989-12-25 1990-12-21 Inhibiteur de croissance de cellules tumorales

Publications (1)

Publication Number Publication Date
KR920700671A true KR920700671A (ko) 1992-08-10

Family

ID=18259725

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700779A KR920700671A (ko) 1989-12-25 1990-12-21 종양세포 증식 억제제

Country Status (13)

Country Link
US (1) US5972879A (ko)
EP (1) EP0460232B1 (ko)
JP (1) JP2997488B2 (ko)
KR (1) KR920700671A (ko)
AT (1) ATE164075T1 (ko)
AU (1) AU635802B2 (ko)
CA (1) CA2044621A1 (ko)
DE (1) DE69032158T2 (ko)
DK (1) DK0460232T3 (ko)
ES (1) ES2113370T3 (ko)
NO (1) NO913322D0 (ko)
RU (1) RU2034564C1 (ko)
WO (1) WO1991009612A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021612A1 (fr) 1999-09-20 2001-03-29 Amato Pharmaceutical Products, Ltd. Procede de preparation d'oligomeres cycliques d'acide lactique
JP2002275256A (ja) * 2001-03-19 2002-09-25 Tendou Seiyaku Kk 乳酸オリゴマーの製造方法
RU2283654C1 (ru) * 2005-03-30 2006-09-20 Борис Владимирович Афанасьев Способ получения ростовых факторов белковой природы, ростовой фактор белковой природы и ингибитор пролиферации фибробластов

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
EP0115473A3 (de) * 1983-01-27 1987-01-21 Ciba-Geigy Ag Substituierte Pyrrolidinonderivate und Verfahren zu ihrer Herstellung
FI840260A (fi) * 1983-01-27 1984-07-28 Ciba Geigy Ag Pyrrolidinonderivat och foerfarande foer deras framstaellning.
EP0127426A1 (en) * 1983-05-23 1984-12-05 Takeda Chemical Industries, Ltd. Percutaneous pharmaceutical compositions for external use
JPS6023326A (ja) * 1983-07-18 1985-02-05 Takeda Chem Ind Ltd ペプチド含有経口投与製剤
DE3428372A1 (de) * 1984-08-01 1986-02-13 Hoechst Ag, 6230 Frankfurt Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
JPS6163613A (ja) * 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc 顆粒状に調整された徐放性製剤

Also Published As

Publication number Publication date
AU6912791A (en) 1991-07-24
AU635802B2 (en) 1993-04-01
CA2044621A1 (en) 1991-06-26
WO1991009612A1 (fr) 1991-07-11
RU2034564C1 (ru) 1995-05-10
NO913322L (no) 1991-08-23
DE69032158D1 (de) 1998-04-23
JP2997488B2 (ja) 2000-01-11
US5972879A (en) 1999-10-26
EP0460232B1 (en) 1998-03-18
EP0460232A1 (en) 1991-12-11
DE69032158T2 (de) 1998-08-06
JPH03193731A (ja) 1991-08-23
EP0460232A4 (en) 1993-03-17
ATE164075T1 (de) 1998-04-15
ES2113370T3 (es) 1998-05-01
NO913322D0 (no) 1991-08-23
DK0460232T3 (da) 1998-04-14

Similar Documents

Publication Publication Date Title
KR910000802A (ko) 흡수성 수지의 제조방법
KR840002416A (ko) 신규 아크릴 공중합체의 제조방법
ES2057577T3 (es) Producto de revestimiento a base de polimeros con contenido en grupos carboxilos y reticulantes con contenido en grupos epoxidos, procedimiento para la preparacion del producto de revestimiento y su utilizacion.
KR950702714A (ko) 포지티브 작용성 방사선 민감성 혼합물 및 이로부터 제조된 기록물질 (Positive-acting radiation-sensitive mixture and recording material produced therewith)
KR830010142A (ko) 안정화된 열경화성 에틸렌성 불포화 에폭시 에스테르 수지 조성물
HUT54655A (en) Process for producing substituted (quinolin-2-ylmethoxy)-phenylacyl sulfonamides and cyanamides, as well as pharmaceutical compositions comprising same
FR2619382B1 (fr) Compose organo-mineral de vanadyle, procede d'obtention d'un tel compose, composition pharmaceutique contenant ce compose organo-mineral
KR920700671A (ko) 종양세포 증식 억제제
US2609387A (en) Removal of amine inhibitors from unsaturated monomers
KR890014783A (ko) 금속표면 처리방법
KR890005195A (ko) 블록화된 산촉매
KR840004120A (ko) 아즈렌 유도체의 안정화 아즈렌 유도체의 안정화방법
KR930019618A (ko) (1,2-나프토퀴논 2-디아지드)설폰산 에스테르, 이를 사용하여 제조된 방사선-감수성 혼합물 및 방사선-감수성 기록 물질
KR910011869A (ko) 결정형 발프로산 마그네슘 및 그 제조방법
KR910007943A (ko) N-디클로로포스포릴트리클로로포스파젠 및 그의 중축합 생성물의 불순물의 해로운 영향 보완 방법.
Martinez et al. Corrosion Inhibitors
KR930021176A (ko) 피록시캄 정 및 그의 제조방법
FR2401944A1 (fr) Procede de production de resines polyesters non-saturees, regulierement reticulees
KR900006431A (ko) 분말 피복 수지조성물
KR890007101A (ko) 열방성 액정 중합체
GB1157741A (en) A process for the manufacture of Aminomethylene-Malononitrile
KR870002051A (ko) L-페닐 알라닌 에스테르의 제조 방법
Grahl-Nielsen et al. Gas–liquid chromatographic separation of amino-acid derivatives
KR910007519A (ko) 스코폴아민을 함유하는 점착제형 경피용 패치
KR920002134A (ko) 분말분사형 에어졸 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid